# David Nikodem

> David Nikodem is a Series A investor at Ally Bridge Group backing Therapeutics and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group)
- Total investments: 1
- Last investment: Sep 2015
- Lead investor: 100%
- Last updated: Aug 2026

David Nikodem is a Series A investor at Ally Bridge Group focused on Therapeutics and Biotechnology. David Nikodem - Managing Director @ Ally Bridge Group

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tunitas Therapeutics | Tunitas Therapeutics is a privately held biopharmaceutical company that is poised to develop unique and precisely targeted protein therapeutics that will dramatically change the lives of allergy sufferers. With Tunitas’ proteins, patients receive a treatment regimen in their allergist’s office that will alter the natural course of their disease,providing a therapeutic option with long-lasting benefit. | $10M | Series A | Sep 30, 2015 |  |

1 of 1 investments shown.

## Co-investors
- [RA Capital Advisors LLC](https://shizune.co/investors/profile/ra-capital-advisors-llc) — VC Fund, 1 deal together
- [WuXi Healthcare Ventures](https://shizune.co/investors/profile/wuxi-healthcare-ventures) — VC Fund, 1 deal together

## About Ally Bridge Group

VC Fund · Hong Kong, Hong Kong

Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing. Ally Bridge Group focuses on both private and public equity investments, with a particular emphasis on pioneering life sciences companies and technologies. The firm is dedicated to bridging the gap betweengroundbreaking healthcare innovations and global markets. By leveraging its expertise and extensive network, Ally Bridge Group supports the growth and development of its portfolio companies. Its investment strategy is centered on transformative technologies and solutions that address major unmet medical needs.

5 contacts available at Ally Bridge Group.

| Name | Title | Profile |
| --- | --- | --- |
| Steven Plachtyna | Vice President | https://shizune.co/investors/profile/steven-plachtyn |
| Arthur Kuan | Founding Member | https://shizune.co/investors/profile/arthur-kuan |
| David Nikodem | Managing Director | https://shizune.co/investors/profile/david-nikodem |
| Dayu Teng | Venture Partner | https://shizune.co/investors/profile/dayu-teng |
| Frank Yu | Founder and CEO | https://shizune.co/investors/profile/frank-yu-3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Nikodem invest in?

David Nikodem invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Nikodem last invest?

The most recent investment recorded for David Nikodem closed in Sep 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co